D. Watkins

发表

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.

Sue Chua, Alex Pearson, James Campbell, 2016, Cancer discovery.

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.

M. Ayers, J. Tabernero, Tae Won Kim, 2015, Journal of the National Cancer Institute.

Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally ad

Y. Bang, J. Bendell, M. Alsina, 2014 .

Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice

M. Gerlinger, C. Braconi, A. Wotherspoon, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of the anti-IGFR antibody MK-0646 in combination with cetuximab and irinotecan in the treatment of chemorefractory metastatic colorectal cancer.

F. J. Ramos, D. Cunningham, H. Schmoll, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.

Gina Brown, D. Cunningham, N. Turner, 2015 .

A prospective study of oxaliplatin and capecitabine (CapOx) in metastatic colorectal cancer (MCRC) with baseline stratification according to resectability status

A. Norman, Gina Brown, D. Cunningham, 2007 .

A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status.

F. J. Ramos, D. Cunningham, H. Schmoll, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab for the treatment of HER 2 positive advanced gastric cancer

D. Watkins, 2010 .

145OPhase II study of AZD4547 in FGFR amplified tumours: gastroesophageal cancer (GC) cohort clinical and translational results

Gina Brown, D. Cunningham, N. Turner, 2015 .

Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial

M. Ayers, J. Tabernero, Tae Won Kim, 2017, International journal of cancer.

A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.

D. Cunningham, G. Brown, I. Chau, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.

D. Cunningham, G. Brown, I. Chau, 2014, European journal of cancer.

Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).

J. Bendell, A. Ko, F. Rivera, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.

C. Ryan, S. Ashley, M. O'Brien, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.

A. Horwich, A. Norman, R. Agarwal, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.

D. Dunlop, C. Fegan, D. Cunningham, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status

A. Norman, D. Cunningham, G. Brown, 2010, British Journal of Cancer.

The combination of a chemotherapy doublet (gemcitabine plus capecitabine) with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma: The TARGET study.

D. Cunningham, I. Chau, K. Thomas, 2010 .

CARRIE: A randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer.

J. Bendell, A. Ko, D. Watkins, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

443P EMERGE: A phase II trial assessing the efficacy of domatinostat plus avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal cancers – phase IIA dose finding

I. Chau, C. Fribbens, C. Peckitt, 2021, Annals of Oncology.

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.

D. Cunningham, K. Fenwick, Jian Ning, 2016, Cancer discovery.

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.

M. Ayers, J. Tabernero, A. Loboda, 2015, Journal of the National Cancer Institute.

Y. Bang, J. Bendell, M. Alsina, 2014 .

A dose-escalation study of gemcitabine (Gem) plus oxaliplatin (Ox) in combination with imatinib in patients (pts) with gemcitabine-refractory advanced pancreatic adenocarcinoma (PC).

D. Cunningham, I. Chau, K. Thomas, 2010 .

Activity of the anti-IGF-1R antibody dalotuzumab (MK-0646) in KRAS-mutant colorectal cancer: Preclinical and clinical data

M. Ayers, G. Naumov, J. Tabernero, 2012 .

Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.

D. Cunningham, N. Turner, N. Smith, 2016 .